{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:45:07Z","timestamp":1792107907944,"version":"4.4.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing-Tianjin-Hebei Natural Science Foundation Cooperation Project","award":["25JJJJC0031"],"award-info":[{"award-number":["25JJJJC0031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00467-026-07442-z","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:57:51Z","timestamp":1783299471000},"page":"4355-4367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New therapeutic hope for rare podocytopathies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-1559","authenticated-orcid":false,"given":"Yanqin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-2128","authenticated-orcid":false,"given":"Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"7442_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","volume":"402","author":"M Vivarelli","year":"2023","unstructured":"Vivarelli M, Gibson K, Sinha A, Boyer O (2023) Childhood nephrotic syndrome. Lancet 402:809\u2013824. https:\/\/doi.org\/10.1016\/S0140-6736(23)01051-6","journal-title":"Lancet"},{"key":"7442_CR2","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ndt\/gfab016","volume":"37","author":"MVD Broek","year":"2022","unstructured":"Broek MVD, Smeets B, Schreuder MF, Jansen J (2022) The podocyte as a direct target of glucocorticoids in nephrotic syndrome. Nephrol Dial Transplant 37:1808\u20131815. https:\/\/doi.org\/10.1093\/ndt\/gfab016","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","volume":"6","author":"JB Kopp","year":"2020","unstructured":"Kopp JB, Anders HJ, Susztak K, Podest\u00e0 MA, Remuzzi G, Hildebrandt F, Romagnani P (2020) Podocytopathies. Nat Rev Dis Primers 6:68. https:\/\/doi.org\/10.1038\/s41572-020-0196-7","journal-title":"Nat Rev Dis Primers"},{"key":"7442_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/sj.ki.5002222","volume":"71","author":"RC Wiggins","year":"2007","unstructured":"Wiggins RC (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71:1205\u20131214. https:\/\/doi.org\/10.1038\/sj.ki.5002222","journal-title":"Kidney Int"},{"key":"7442_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1681\/ASN.0000000520","volume":"36","author":"P Gauckler","year":"2025","unstructured":"Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, King C, Griffin S, Ramachandran R, Odler B, Eller K (2025) Long-term outcomes of rituximab-treated adult patients with podocytopathies. J Am Soc Nephrol 36:668\u2013678. https:\/\/doi.org\/10.1681\/ASN.0000000520","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/HJH.0000000000001170","volume":"35","author":"TM Seccia","year":"2017","unstructured":"Seccia TM, Caroccia B, Cal\u00f2 LA (2017) Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens 35:205\u2013212. https:\/\/doi.org\/10.1097\/HJH.0000000000001170","journal-title":"J Hypertens"},{"key":"7442_CR7","doi-asserted-by":"publisher","first-page":"3172647","DOI":"10.1155\/2019\/3172647","volume":"2019","author":"J Zhao","year":"2019","unstructured":"Zhao J, Rui HL, Yang M, Sun LJ, Dong HR, Cheng H (2019) CD36-mediated lipid accumulation and activation of NLRP3 inflammasome lead to podocyte injury in obesity-related glomerulopathy. Mediators Inflamm 2019:3172647. https:\/\/doi.org\/10.1155\/2019\/3172647","journal-title":"Mediators Inflamm"},{"key":"7442_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ki.2014.48","volume":"85","author":"EJ Brown","year":"2014","unstructured":"Brown EJ, Pollak MR, Barua M (2014) Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. Kidney Int 85:1030\u20131038. https:\/\/doi.org\/10.1038\/ki.2014.48","journal-title":"Kidney Int"},{"key":"7442_CR9","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.34067\/KID.0000812022","volume":"3","author":"S Hara","year":"2022","unstructured":"Hara S, Yoshikawa N, Takeda A, Gotoh Y, Hamada R, Matsuoka K, Yamamoto M, Fujinaga S, Sakuraya K, Kamei K, Hamasaki Y (2022) Clinical, pathological, and genetic characteristics in patients with focal segmental glomerulosclerosis. Kidney360 3:1384\u20131393. https:\/\/doi.org\/10.34067\/KID.0000812022","journal-title":"Kidney360"},{"key":"7442_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41581-024-00843-z","volume":"20","author":"K Meliambro","year":"2024","unstructured":"Meliambro K, He JC, Campbell KN (2024) Podocyte-targeted therapies - progress and future directions. Nat Rev Nephrol 20:643\u2013658. https:\/\/doi.org\/10.1038\/s41581-024-00843-z","journal-title":"Nat Rev Nephrol"},{"key":"7442_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.molmed.2005.10.001","volume":"11","author":"W Kriz","year":"2005","unstructured":"Kriz W (2005) TRPC6 - a new podocyte gene involved in focal segmental glomerulosclerosis. Trends Mol Med 11:527\u2013530. https:\/\/doi.org\/10.1016\/j.molmed.2005.10.001","journal-title":"Trends Mol Med"},{"key":"7442_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/ndt\/gfaf086","volume":"41","author":"SM McAnallen","year":"2025","unstructured":"McAnallen SM, Elhassan EAE, Stoneman S, Pinto E, Vairo F, Hogan MC, Hoefele J, Clince M, Mekraksakit P, Titan SM, Jorge S, Calado J, Decramer S, Colliou E, Tellier S, Francisco T, Servais A, Cornet J, de Fallois J, Dossier C, Fenoglio R, Renieri A, Pinto AM, Daga S, Loberti L, Fila M, Quintana LF, Becherucci F, Godefroid N, Dubrasquet A, K\u00e1lm\u00e1n T, Dolan N, Alawi BA, Sweeney C, Riordan M, Stack M, Awan A, Hui NK, McCarthy HJ, Biros E, Harris T, Kidd K, Haeberle S, Bleyer AJ, Mallett AJ, Sayer JA, Schafer F, Benson KA, McCann E, Conlon PJ (2025) Genotype-phenotype correlations and clinical outcomes of genetic TRPC6 podocytopathies. Nephrol Dial Transplant 41:79\u201391. https:\/\/doi.org\/10.1093\/ndt\/gfaf086","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41572-025-00671-w","volume":"11","author":"P Romagnani","year":"2025","unstructured":"Romagnani P, Tang SCW, Weins A, Huber TB, Osafo C, Anders HJ (2025) Podocytopathies. Nat Rev Dis Primers 11:87. https:\/\/doi.org\/10.1038\/s41572-025-00671-w","journal-title":"Nat Rev Dis Primers"},{"key":"7442_CR14","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1681\/ASN.2006080833","volume":"18","author":"F Diomedi-Camassei","year":"2007","unstructured":"Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, Emma F (2007) COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 18:2773\u20132780. https:\/\/doi.org\/10.1681\/ASN.2006080833","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/ndt\/gfv325","volume":"31","author":"C Gast","year":"2016","unstructured":"Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, Venkat-Raman G, Ennis S (2016) Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 31:961\u2013970. https:\/\/doi.org\/10.1093\/ndt\/gfv325","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR16","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1172\/JCI28414","volume":"116","author":"G Jarad","year":"2006","unstructured":"Jarad G, Cunningham J, Shaw AS, Miner JH (2006) Proteinuria precedes podocyte abnormalities in Lamb2-\/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 116:2272\u20132279. https:\/\/doi.org\/10.1172\/JCI28414","journal-title":"J Clin Invest"},{"key":"7442_CR17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.kint.2017.05.017","volume":"92","author":"F Ding","year":"2017","unstructured":"Ding F, Wickman L, Wang SQ, Zhang Y, Wang F, Afshinnia F, Hodgin J, Ding J, Wiggins RC (2017) Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport syndrome. Kidney Int 92:1515\u20131525. https:\/\/doi.org\/10.1016\/j.kint.2017.05.017","journal-title":"Kidney Int"},{"key":"7442_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.5969","volume":"258","author":"J Madison","year":"2022","unstructured":"Madison J, Wilhelm K, Meehan DT, Delimont D, Samuelson G, Cosgrove D (2022) Glomerular basement membrane deposition of collagen \u03b11(III) in Alport glomeruli by mesangial filopodia injures podocytes via aberrant signaling through DDR1 and integrin \u03b12\u03b21. J Pathol 258:26\u201337. https:\/\/doi.org\/10.1002\/path.5969","journal-title":"J Pathol"},{"key":"7442_CR19","doi-asserted-by":"publisher","first-page":"168008","DOI":"10.1016\/j.bbadis.2025.168008","volume":"1871","author":"K Uchio-Yamada","year":"2025","unstructured":"Uchio-Yamada K, Yasuda K, Suzuki O, Oh-Hashi K, Ohta T, Manabe N (2025) Ectopic laminin \u03b12 accumulation in the glomerular basement membrane exacerbates podocyte injury in Alport syndrome. Biochim Biophys Acta Mol Basis Dis 1871:168008. https:\/\/doi.org\/10.1016\/j.bbadis.2025.168008","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"7442_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.kint.2016.10.013","volume":"91","author":"A Bierzynska","year":"2017","unstructured":"Bierzynska A, McCarthy HJ, Soderquest K, Sen ES, Colby E, Ding WY, Nabhan MM, Kerecuk L, Hegde S, Hughes D, Marks S, Feather S, Jones C, Webb NJ, Ognjanovic M, Christian M, Gilbert RD, Sinha MD, Lord GM, Simpson M, Koziell AB, Welsh GI, Saleem MA (2017) Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int 91:937\u2013947. https:\/\/doi.org\/10.1016\/j.kint.2016.10.013","journal-title":"Kidney Int"},{"key":"7442_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1681\/ASN.2014050489","volume":"26","author":"CE Sadowski","year":"2015","unstructured":"Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, Engelmann S, Vega-Warner V, Fang H, Halbritter J, Somers MJ (2015) A single-gene cause in 295% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 26:1279\u20131289. https:\/\/doi.org\/10.1681\/ASN.2014050489","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR22","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1007\/s00467-024-06468-5","volume":"39","author":"Y Ichikawa","year":"2024","unstructured":"Ichikawa Y, Sakakibara N, Nagano C, Inoki Y, Tanaka Y, Ueda C, Kitakado H, Kondo A, Ishimori S, Horinouchi T, Iijima K, Nozu K (2024) In steroid-resistant nephrotic syndrome that meets the strict definition, monogenic variants are less common than expected. Pediatr Nephrol 39:3497\u20133503. https:\/\/doi.org\/10.1007\/s00467-024-06468-5","journal-title":"Pediatr Nephrol"},{"key":"7442_CR23","doi-asserted-by":"publisher","first-page":"885178","DOI":"10.3389\/fmed.2022.885178","volume":"9","author":"X Zhu","year":"2022","unstructured":"Zhu X, Zhang Y, Yu Z, Yu L, Huang W, Sun S, Li Y, Wang M, Li Y, Sun L, Yang Q, Deng F, Shao X, Liu L, Liu C, Qin Y, Feng S, Zhu H, Yang F, Zheng W, Zheng W, Zhong R, Hou L, Mao J, Wang F, Ding J (2022) The clinical and genetic features in Chinese children with steroid-resistant or early-onset nephrotic syndrome: a multicenter cohort study. Front Med (Lausanne) 9:885178. https:\/\/doi.org\/10.3389\/fmed.2022.885178","journal-title":"Front Med (Lausanne)"},{"key":"7442_CR24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/medicina60111821","volume":"60","author":"E Longhitano","year":"2024","unstructured":"Longhitano E, Calabrese V, Casuscelli C, Di Carlo S, Maltese S, Romeo A, Calanna M, Conti G, Santoro D (2024) Proteinuria and progression of renal damage: the main pathogenetic mechanisms and pharmacological approach. Medicina (Kaunas) 60:1821. https:\/\/doi.org\/10.3390\/medicina60111821","journal-title":"Medicina (Kaunas)"},{"key":"7442_CR25","doi-asserted-by":"publisher","first-page":"847295","DOI":"10.3389\/fped.2022.847295","volume":"10","author":"P Arroyo-Parejo Drayer","year":"2022","unstructured":"Arroyo-Parejo Drayer P, Seeherunvong W, Katsoufis CP, DeFreitas MJ, Seeherunvong T, Chandar J, Abitbol CL (2022) Spectrum of clinical manifestations in children with WT1 mutation: case series and literature review. Front Pediatr 10:847295. https:\/\/doi.org\/10.3389\/fped.2022.847295","journal-title":"Front Pediatr"},{"key":"7442_CR26","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10165.1","volume":"6","author":"A Bierzynska","year":"2017","unstructured":"Bierzynska A, Saleem M (2017) Recent advances in understanding and treating nephrotic syndrome. F1000Res 6:121. https:\/\/doi.org\/10.12688\/f1000research.10165.1","journal-title":"F1000Res"},{"key":"7442_CR27","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"7442_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/hr.2013.86","volume":"36","author":"E Imai","year":"2013","unstructured":"Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, Chan JC, Makino H (2013) Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res 36:1051\u20131059. https:\/\/doi.org\/10.1038\/hr.2013.86","journal-title":"Hypertens Res"},{"key":"7442_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","volume":"63","author":"J Cheng","year":"2009","unstructured":"Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH (2009) ACEI\/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 63:880\u2013888. https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02038.x","journal-title":"Int J Clin Pract"},{"key":"7442_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s13312-021-2262-y","volume":"58","author":"Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, Sinha A, Bagga A; Expert Group Of The Indian Society Of Pediatric Nephrology","year":"2021","unstructured":"Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, Sinha A, Bagga A; Expert Group Of The Indian Society Of Pediatric Nephrology (2021) Consensus guidelines on management of steroid-resistant nephrotic syndrome. Indian Pediatr 58:650\u2013666","journal-title":"Indian Pediatr"},{"key":"7442_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, M\u00fcller-Deile J (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529\u20131561. https:\/\/doi.org\/10.1007\/s00467-020-04519-1","journal-title":"Pediatr Nephrol"},{"key":"7442_CR32","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"E Wuhl","year":"2009","unstructured":"Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A (2009) Strict blood pressure control and renal failure progression in children. N Engl J Med 361:1639\u20131650. https:\/\/doi.org\/10.1056\/NEJMoa0902066","journal-title":"N Engl J Med"},{"key":"7442_CR33","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1681\/ASN.2018010036","volume":"29","author":"SM van den Belt","year":"2018","unstructured":"van den Belt SM, Heerspink HJ, Gracchi V, de Zeeuw D, W\u00fchl E, Schaefer F, ESCAPE Trial Group (2018) Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol 29:2225\u20132233. https:\/\/doi.org\/10.1681\/ASN.2018010036","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004.pub4","volume":"10","author":"EY Chung","year":"2020","unstructured":"Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF (2020) Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 10:CD007004. https:\/\/doi.org\/10.1002\/14651858.CD007004.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"7442_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13063-024-08021-z","volume":"25","author":"F Schaefer","year":"2024","unstructured":"Schaefer F, Montini G, Kang HG, Walle JV, Zaritsky J, Schreuder MF, Litwin M, Scalise A, Scott H, Potts J, Iveli P, Breitenstein S, Warady BA (2024) Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials 25:203. https:\/\/doi.org\/10.1186\/s13063-024-08021-z","journal-title":"Trials"},{"key":"7442_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-015-3184-5","volume":"31","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wang F, Ding J, Zhang H, Liu X, Wang S, Xiao H, Yao Y, Liu J, Zhong X, Guan N, Su B, Wu G, Yu L (2016) Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome. Pediatr Nephrol 31:67\u201372. https:\/\/doi.org\/10.1007\/s00467-015-3184-5","journal-title":"Pediatr Nephrol"},{"key":"7442_CR37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"O Gross","year":"2020","unstructured":"Gross O, T\u00f6nshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, Lange-Sperandio B, Zappel H, Hoyer P, Staude H, K\u00f6nig S (2020) A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome. Kidney Int 97:1275\u20131286. https:\/\/doi.org\/10.1016\/j.kint.2019.12.015","journal-title":"Kidney Int"},{"key":"7442_CR38","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1093\/ndt\/gfac002","volume":"37","author":"H Di","year":"2022","unstructured":"Di H, Zhang J, Gao E, Zheng C, Huang X, Wang Q, Yu X, Liu Z (2022) Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome. Nephrol Dial Transplant 37:2487\u20132495. https:\/\/doi.org\/10.1093\/ndt\/gfac002","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR39","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","volume":"98","author":"T Yamamura","year":"2020","unstructured":"Yamamura T, Horinouchi T, Nagano C, Omori T, Sakakibara N, Aoto Y, Ishiko S, Nakanishi K, Shima Y, Nagase H, Takeda H, Rossanti R, Ye MJ, Nozu Y, Ishimori S, Ninchoji T, Kaito H, Morisada N, Iijima K, Nozu K (2020) Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int 98:1605\u20131614. https:\/\/doi.org\/10.1016\/j.kint.2020.06.038","journal-title":"Kidney Int"},{"key":"7442_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","volume":"81","author":"O Gross","year":"2012","unstructured":"Gross O, Licht C, Anders HJ, Hoppe B, Beck B, T\u00f6nshoff B, H\u00f6cker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, D\u00f6tsch J, M\u00fcller-Wiefel DE, Hoyer P, Study Group Members of the Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, M\u00fcller GA, Weber M (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494\u2013501. https:\/\/doi.org\/10.1038\/ki.2011.407","journal-title":"Kidney Int"},{"key":"7442_CR41","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s00467-021-05040-9","volume":"36","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, B\u00f6ckhaus J, Wang F, Wang S, Rubel D, Gross O, Ding J (2021) Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol 36:2719\u20132730. https:\/\/doi.org\/10.1007\/s00467-021-05040-9","journal-title":"Pediatr Nephrol"},{"key":"7442_CR42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/ki.2011.452","volume":"81","author":"J Temme","year":"2012","unstructured":"Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, M\u00fcller GA, Gross O (2012) Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81:779\u2013783. https:\/\/doi.org\/10.1038\/ki.2011.452","journal-title":"Kidney Int"},{"key":"7442_CR43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","volume":"36","author":"CE Kashtan","year":"2021","unstructured":"Kashtan CE, Gross O (2021) Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol 36:711\u2013719. https:\/\/doi.org\/10.1007\/s00467-020-04819-6","journal-title":"Pediatr Nephrol"},{"key":"7442_CR44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1681\/ASN.2012020148","volume":"24","author":"J Savige","year":"2013","unstructured":"Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013) Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24:364\u2013375. https:\/\/doi.org\/10.1681\/ASN.2012020148","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJ Heerspink","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JF, McMurray JJ, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"7442_CR46","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sj\u00f6str\u00f6m CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators (2021) Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:755\u2013766. https:\/\/doi.org\/10.1016\/S2213-8587(21)00243-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7442_CR47","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1093\/ndt\/gfae106","volume":"39","author":"P McEwan","year":"2024","unstructured":"McEwan P, Gabb PD, Davis JA, Garcia Sanchez JJ, Sj\u00f6str\u00f6m CD, Barone S, Kashioulis P, Ouwens M, Cassimaty S, Correa-Rotter R, Rossing P, Wheeler DC, Heerspink HJL (2024) The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrol Dial Transplant 39:2040\u20132047. https:\/\/doi.org\/10.1093\/ndt\/gfae106","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"7442_CR49","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa240918","volume":"392","author":"WG Herrington","year":"2025","unstructured":"Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med 392:777\u2013787. https:\/\/doi.org\/10.1056\/NEJMoa240918","journal-title":"N Engl J Med"},{"key":"7442_CR50","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano M, Puchades MJ, Garofalo C, Jongs N, D\u2019Marco L, Andreucci M, De Nicola L, Gorriz JL, Heerspink HJL (2022) Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J Am Soc Nephrol 33:1569\u20131580. https:\/\/doi.org\/10.1681\/ASN.2022020207","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR51","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","volume":"37","author":"DC Wheeler","year":"2022","unstructured":"Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF, Langkilde AM, McMurray JJV, Rossing P, Nowicki M, Wittmann I, Correa-Rotter R, Sj\u00f6str\u00f6m CD, Toto RD, Heerspink HJL (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant 37:1647\u20131656. https:\/\/doi.org\/10.1093\/ndt\/gfab335","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR52","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3390\/jcm13040956","volume":"13","author":"AM Abdelrahman","year":"2024","unstructured":"Abdelrahman AM, Awad AS, Abdel-Rahman EM (2024) Sodium-glucose co-transporter 2 inhibitors: mechanism of action and efficacy in non-diabetic kidney disease from bench to bed-side. J Clin Med 13:956. https:\/\/doi.org\/10.3390\/jcm13040956","journal-title":"J Clin Med"},{"key":"7442_CR53","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/cells10071815","volume":"10","author":"J Boeckhaus","year":"2021","unstructured":"Boeckhaus J, Gross O (2021) Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, Alport syndrome, and FSGS: a case series to better plan a large-scale study. Cells 10:1815. https:\/\/doi.org\/10.3390\/cells10071815","journal-title":"Cells"},{"key":"7442_CR54","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1016\/j.ekir.2024.09.014","volume":"9","author":"J Boeckhaus","year":"2024","unstructured":"Boeckhaus J, Gale DP, Simon J, Ding J, Zhang Y, Bergmann C, Turner AN, Hall M, Sayer JA, Srivastava S, Kang HG, Cerkauskaite-Kerpauskiene A, Gillion V, Claes KJ, Krueger B, de Fallois J, Walden U, Choi M, Schueler M, Mueller RU, Todorova P, Hohenstein B, Zeisberg M, Friede T, Knebelmann B, Halbritter J, Gross O (2024) SGLT2-inhibition in patients with Alport syndrome. Kidney Int Rep 9:3490\u20133500. https:\/\/doi.org\/10.1016\/j.ekir.2024.09.014","journal-title":"Kidney Int Rep"},{"key":"7442_CR55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jphs.2025.09.008","volume":"159","author":"J Horizono","year":"2025","unstructured":"Horizono J, Mizumoto K, Suico MA, Kaseda S, Sannomiya Y, Tsuhako H, Owaki A, Sato R, Shiraga M, Kato R, Kumabe R, Shuto T, Kai H (2025) Dapagliflozin with losartan but not olmesartan has an add-on protective effect in experimental Alport syndrome. J Pharmacol Sci 159:252\u2013255. https:\/\/doi.org\/10.1016\/j.jphs.2025.09.008","journal-title":"J Pharmacol Sci"},{"key":"7442_CR56","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Rosenkranz KAT, Kusunoki Y, Li C, Klaus M, Gross O, Angelotti ML, Antonelli G, Cirillo L, Romagnani P, Bouteldja N, Sadr AV, B\u00fclow RD, Boor P, Anders HJ (2023) Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. Results of a randomized controlled trial with Col4a3-\/- mice. J Am Soc Nephrol 34:1513\u20131520. https:\/\/doi.org\/10.1681\/ASN.0000000000000186","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR57","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/ndt\/gfae265","volume":"40","author":"R Torra","year":"2025","unstructured":"Torra R, Lipska-Zietkiewicz B, Acke F, Antignac C, Becker JU, Cornec-Le Gall E, van Eerde AM, Feltgen N, Ferrari R, Gale DP, Gear S, Gross O, Haeberle S, Heidet L, Lennon R, Massella L, Pfau K, Pizarro MDPV, Topaloglu R, Wlodkowski T, Zealey H (2025) Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant 40:1091\u20131106. https:\/\/doi.org\/10.1093\/ndt\/gfae265","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ndt\/gfae180","volume":"40","author":"Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R, Gerst C, Duerr U, Walker F, Tostmann R, Helm J, Asendorf T, Friede T; study group of the German Society of Pediatric Nephrology","year":"2025","unstructured":"Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R, Gerst C, Duerr U, Walker F, Tostmann R, Helm J, Asendorf T, Friede T; study group of the German Society of Pediatric Nephrology (2025) Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrol Dial Transplant 40:679\u2013687. https:\/\/doi.org\/10.1093\/ndt\/gfae180","journal-title":"Nephrol Dial Transplant"},{"key":"7442_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","volume":"21","author":"JD Smeijer","year":"2025","unstructured":"Smeijer JD, Kohan DE, Dhaun N, Noronha IL, Liew A, Heerspink HJL (2025) Endothelin receptor antagonists in chronic kidney disease. Nat Rev Nephrol 21:175\u2013188. https:\/\/doi.org\/10.1038\/s41581-024-00908-z","journal-title":"Nat Rev Nephrol"},{"key":"7442_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00060.2009","volume":"91","author":"DE Kohan","year":"2011","unstructured":"Kohan DE, Rossi NF, Inscho EW, Pollock DM (2011) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91:1\u201377. https:\/\/doi.org\/10.1152\/physrev.00060.2009","journal-title":"Physiol Rev"},{"key":"7442_CR61","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1172\/JCI71195","volume":"124","author":"I Daehn","year":"2014","unstructured":"Daehn I, Casalena G, Zhang T, Shi S, Fenninger F, Barasch N, Yu L, D\u2019Agati V, Schlondorff D, Kriz W, Haraldsson B, Bottinger EP (2014) Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 124:1608\u20131621. https:\/\/doi.org\/10.1172\/JCI71195","journal-title":"J Clin Invest"},{"key":"7442_CR62","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1681\/ASN.2013040362","volume":"25","author":"S Buelli","year":"2014","unstructured":"Buelli S, Rosan\u00f2 L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A (2014) \u03b2-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol 25:523\u2013533. https:\/\/doi.org\/10.1681\/ASN.2013040362","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR63","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Ma\u0142ecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402:2077\u20132090. https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4","journal-title":"Lancet"},{"key":"7442_CR64","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","volume":"389","author":"MN Rheault","year":"2023","unstructured":"Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H, DUPRO Steering Committee and DUPLEX Investigators (2023) Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N Engl J Med 389:2436\u20132445. https:\/\/doi.org\/10.1056\/NEJMoa2308550","journal-title":"N Engl J Med"},{"key":"7442_CR65","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.kint.2016.02.018","volume":"90","author":"B Dufek","year":"2016","unstructured":"Dufek B, Meehan DT, Delimont D, Cheung L, Gratton MA, Phillips G, Song W, Liu S, Cosgrove D (2016) Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease. Kidney Int 90:300\u2013310. https:\/\/doi.org\/10.1016\/j.kint.2016.02.018","journal-title":"Kidney Int"},{"key":"7442_CR66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/path.6087","volume":"260","author":"D Cosgrove","year":"2023","unstructured":"Cosgrove D, Gratton MA, Madison J, Vosik D, Samuelson G, Meehan D, Delimont D, Phillips G, Smyth B, Pramparo T, Jarocki D, Nguyen M, Komers R, Jenkinson C (2023) Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J Pathol 260:353\u2013364. https:\/\/doi.org\/10.1002\/path.6087","journal-title":"J Pathol"},{"key":"7442_CR67","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1016\/j.ekir.2024.07.027","volume":"9","author":"ZR Song","year":"2024","unstructured":"Song ZR, Li Y, Zhang H, Zhou XJ (2024) A pilot study on protective effect of ambrisentan on proteinuria in patients with Alport syndrome. Kidney Int Rep 9:3067\u20133069. https:\/\/doi.org\/10.1016\/j.ekir.2024.07.027","journal-title":"Kidney Int Rep"},{"key":"7442_CR68","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1172\/JCI45693","volume":"121","author":"SF Heeringa","year":"2011","unstructured":"Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, Xie LX, Salviati L, Hurd TW, Vega-Warner V, Killen PD, Raphael Y, Ashraf S, Ovunc B, Schoeb DS, McLaughlin HM, Airik R, Vlangos CN, Gbadegesin R, Hinkes B, Saisawat P, Trevisson E, Doimo M, Casarin A, Pertegato V, Giorgi G, Prokisch H, R\u00f6tig A, N\u00fcrnberg G, Becker C, Wang S, Ozaltin F, Topaloglu R, Bakkaloglu A, Bakkaloglu SA, M\u00fcller D, Beissert A, Mir S, Berdeli A, Varpizen S, Zenker M, Matejas V, Santos-Oca\u00f1a C, Navas P, Kusakabe T, Kispert A, Akman S, Soliman NA, Krick S, Mundel P, Reiser J, N\u00fcrnberg P, Clarke CF, Wiggins RC, Faul C, Hildebrandt F (2011) COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 121:2013\u20132024. https:\/\/doi.org\/10.1172\/JCI45693","journal-title":"J Clin Invest"},{"key":"7442_CR69","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10545-014-9749-9","volume":"38","author":"MA Desbats","year":"2015","unstructured":"Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L (2015) Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. J Inherit Metab Dis 38:145\u2013156. https:\/\/doi.org\/10.1007\/s10545-014-9749-9","journal-title":"J Inherit Metab Dis"},{"key":"7442_CR70","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.4103\/0366-6999.245158","volume":"131","author":"CC Song","year":"2018","unstructured":"Song CC, Hong Q, Geng XD, Wang X, Wang SQ, Cui SY, Guo MD, Li O, Cai GY, Chen XM, Wu D (2018) New mutation of coenzyme Q10 monooxygenase 6 causing podocyte injury in a focal segmental glomerulosclerosis patient. Chin Med J (Engl) 131:2666\u20132675. https:\/\/doi.org\/10.4103\/0366-6999.245158","journal-title":"Chin Med J (Engl)"},{"key":"7442_CR71","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.kint.2022.04.029","volume":"102","author":"Drovandi S, Lipska-Zi\u0119tkiewicz BS, Ozaltin F, Emma F, Gulhan B, Boyer O, Trautmann A, Xu H, Shen Q, Rao J, Riedhammer KM, Heemann U, Hoefele J, Stenton SL, Tsygin AN, Ng KH, Fomina S, Benetti E, Aurelle M, Prikhodina L, Schreuder MF, Tabatabaeifar M, Jankowski M, Baiko S, Mao J, Feng C, Liu C, Sun S, Deng F, Wang X, Clav\u00e9 S, Sta\u0144czyk M, Ba\u0142asz-Chmielewska I, Fila M, Durkan AM, Levart TK, Dursun I, Esfandiar N, Haas D, Bjerre A, Anarat A, Benz MR, Talebi S, Hooman N, Ariceta G; PodoNet Consortium; mitoNET Consortium; CCGKDD Consortium; Schaefer F","year":"2022","unstructured":"Drovandi S, Lipska-Zi\u0119tkiewicz BS, Ozaltin F, Emma F, Gulhan B, Boyer O, Trautmann A, Xu H, Shen Q, Rao J, Riedhammer KM, Heemann U, Hoefele J, Stenton SL, Tsygin AN, Ng KH, Fomina S, Benetti E, Aurelle M, Prikhodina L, Schreuder MF, Tabatabaeifar M, Jankowski M, Baiko S, Mao J, Feng C, Liu C, Sun S, Deng F, Wang X, Clav\u00e9 S, Sta\u0144czyk M, Ba\u0142asz-Chmielewska I, Fila M, Durkan AM, Levart TK, Dursun I, Esfandiar N, Haas D, Bjerre A, Anarat A, Benz MR, Talebi S, Hooman N, Ariceta G; PodoNet Consortium; mitoNET Consortium; CCGKDD Consortium; Schaefer F (2022) Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int 102:604\u2013612. https:\/\/doi.org\/10.1016\/j.kint.2022.04.029","journal-title":"Kidney Int"},{"key":"7442_CR72","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1258\/ebm.2010.010237","volume":"236","author":"L Jiang","year":"2011","unstructured":"Jiang L, Ding J, Tsai H, Li L, Feng Q, Miao J, Fan Q (2011) Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation. Exp Biol Med (Maywood) 236:184\u2013193. https:\/\/doi.org\/10.1258\/ebm.2010.010237","journal-title":"Exp Biol Med (Maywood)"},{"key":"7442_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/13543784.2025.2510673","volume":"34","author":"A Schultz","year":"2025","unstructured":"Schultz A, Halabi A, Seitz F, Lemmens K, W\u00fclfrath HS, Lobmeyer MT, Retlich S, Choi W, Soleymanlou N (2025) Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment. Expert Opin Investig Drugs 34:415\u2013423. https:\/\/doi.org\/10.1080\/13543784.2025.2510673","journal-title":"Expert Opin Investig Drugs"},{"key":"7442_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc8226","volume":"15","author":"WY Ding","year":"2023","unstructured":"Ding WY, Kuzmuk V, Hunter S, Lay A, Hayes B, Beesley M, Rollason R, Hurcombe JA, Barrington F, Masson C, Cathery W, May C, Tuffin J, Roberts T, Mollet G, Chu CJ, McIntosh J, Coward RJ, Antignac C, Nathwani A, Welsh GI, Saleem MA (2023) Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome. Sci Transl Med 15:eabc8226. https:\/\/doi.org\/10.1126\/scitranslmed.abc8226","journal-title":"Sci Transl Med"},{"key":"7442_CR75","doi-asserted-by":"publisher","first-page":"e145936","DOI":"10.1172\/jci.insight.145936","volume":"6","author":"P Zhao","year":"2021","unstructured":"Zhao P, Tassew GB, Lee JY, Oskouian B, Mu\u00f1oz DP, Hodgin JB, Watson GL, Tang F, Wang JY, Luo J, Yang Y, King S, Krauss RM, Keller N, Saba JD (2021) Efficacy of AAV9-mediated SGPL1 gene transfer in a mouse model of S1P lyase insufficiency syndrome. JCI Insight 6:e145936. https:\/\/doi.org\/10.1172\/jci.insight.145936","journal-title":"JCI Insight"},{"key":"7442_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115560","volume":"24","author":"R Khan","year":"2023","unstructured":"Khan R, Oskouian B, Lee JY, Hodgin JB, Yang Y, Tassew G, Saba JD (2023) AAV-SPL 2.0, a modified adeno-associated virus gene therapy agent for the treatment of sphingosine phosphate lyase insufficiency syndrome. Int J Mol Sci 24:15560. https:\/\/doi.org\/10.3390\/ijms242115560","journal-title":"Int J Mol Sci"},{"key":"7442_CR77","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1681\/ASN.2018030228","volume":"29","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori T, Nakanishi K, Fujimura J, Ashida A, Kitamura M, Kawano M, Shimabukuro W, Kitabayashi C, Imafuku A, Tamagaki K, Kamei K, Okamoto K, Fujinaga S, Oka M, Igarashi T, Miyazono A, Sawanobori E, Fujimaru R, Nakanishi K, Shima Y, Matsuo M, Ye MJ, Nozu Y, Morisada N, Kaito H, Iijima K (2018) Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 29:2244\u20132254. https:\/\/doi.org\/10.1681\/ASN.2018030228","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR78","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","volume":"11","author":"T Yamamura","year":"2020","unstructured":"Yamamura T, Horinouchi T, Adachi T, Terakawa M, Takaoka Y, Omachi K, Takasato M, Takaishi K, Shoji T, Onishi Y, Kanazawa Y, Koizumi M, Tomono Y, Sugano A, Shono A, Minamikawa S, Nagano C, Sakakibara N, Ishiko S, Aoto Y, Kamura M, Harita Y, Miura K, Kanda S, Morisada N, Rossanti R, Ye MJ, Nozu Y, Matsuo M, Kai H, Iijima K, Nozu K (2020) Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5. Nat Commun 11:2777. https:\/\/doi.org\/10.1038\/s41467-020-16605-x","journal-title":"Nat Commun"},{"key":"7442_CR79","doi-asserted-by":"publisher","first-page":"41766","DOI":"10.1038\/s41598-025-25447-w","volume":"15","author":"K Hashikami","year":"2025","unstructured":"Hashikami K, Kobayashi R, Hori R, Danbayashi K, Nio Y (2025) Podocyte specific exon skipping after disease onset improves kidney pathology and function in a mouse model of Alport syndrome. Sci Rep 15:41766. https:\/\/doi.org\/10.1038\/s41598-025-25447-w","journal-title":"Sci Rep"},{"key":"7442_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103891","volume":"25","author":"K Omachi","year":"2022","unstructured":"Omachi K, Kai H, Roberge M, Miner JH (2022) NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough. iScience 25:103891. https:\/\/doi.org\/10.1016\/j.isci.2022.103891","journal-title":"iScience"},{"key":"7442_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0330804","volume":"20","author":"K Omachi","year":"2025","unstructured":"Omachi K, Porter JJ, Lueck JD, Miner JH (2025) Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons. PLoS One 20:e0330804. https:\/\/doi.org\/10.1371\/journal.pone.0330804","journal-title":"PLoS One"},{"key":"7442_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf246","volume":"18","author":"V D'Ambrosio","year":"2025","unstructured":"D\u2019Ambrosio V, Huimei C, Vo N, Siew K, Evans RDR, Freedman B, Pesce F (2025) CRISPR and gene editing for kidney diseases: where are we? Clin Kidney J 18:sfaf246. https:\/\/doi.org\/10.1093\/ckj\/sfaf246","journal-title":"Clin Kidney J"},{"key":"7442_CR83","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41431-019-0537-8","volume":"28","author":"S Daga","year":"2020","unstructured":"Daga S, Donati F, Capitani K, Croci S, Tita R, Giliberti A, Valentino F, Benetti E, Fallerini C, Niccheri F, Baldassarri M, Mencarelli MA, Frullanti E, Furini S, Conticello SG, Renieri A, Pinto AM (2020) New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells. Eur J Hum Genet 28:480\u2013490. https:\/\/doi.org\/10.1038\/s41431-019-0537-8","journal-title":"Eur J Hum Genet"},{"key":"7442_CR84","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.kint.2023.11.029","volume":"105","author":"Z Chen","year":"2024","unstructured":"Chen Z, Zhang D, Zheng R, Yang L, Huo Y, Zhang D, Fang X, Li Y, Xu G, Li D, Geng H (2024) In vivo base editing rescues primary hyperoxaluria type 1 in rats. Kidney Int 105:496\u2013507. https:\/\/doi.org\/10.1016\/j.kint.2023.11.029","journal-title":"Kidney Int"},{"key":"7442_CR85","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1089\/hum.2018.205","volume":"30","author":"J Guo","year":"2019","unstructured":"Guo J, Song W, Boulanger J, Xu EY, Wang F, Zhang Y, He Q, Wang S, Yang L, Pryce C, Phillips L, MacKenna D, Leberer E, Ibraghimov-Beskrovnaya O, Ding J, Liu S (2019) Dysregulated expression of microRNA-21 and disease-related genes in human patients and in a mouse model of Alport syndrome. Hum Gene Ther 30:865\u2013881. https:\/\/doi.org\/10.1089\/hum.2018.205","journal-title":"Hum Gene Ther"},{"key":"7442_CR86","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/cells11040594","volume":"11","author":"D Rubel","year":"2022","unstructured":"Rubel D, Boulanger J, Craciun F, Xu EY, Zhang Y, Phillips L, Callahan M, Weber W, Song W, Ngai N, Bukanov NO, Shi X, Hariri A, Husson H, Ibraghimov-Beskrovnaya O, Liu S, Gross O (2022) Anti-microRNA-21 therapy on top of ACE inhibition delays renal failure in Alport syndrome mouse models. Cells 11:594. https:\/\/doi.org\/10.3390\/cells11040594","journal-title":"Cells"},{"key":"7442_CR87","doi-asserted-by":"publisher","first-page":"9951004","DOI":"10.2215\/CJN.0000000000000458","volume":"19","author":"Gale DP, Gross O, Wang F, Esteban de la Rosa RJ, Hall M, Sayer JA, Appel G, Hariri A, Liu S, Maski M, Shen Y, Zhang Q, Iqbal S, Kowthalam MU, Lin J, Ding J; HERA Clinical Trial Group","year":"2024","unstructured":"Gale DP, Gross O, Wang F, Esteban de la Rosa RJ, Hall M, Sayer JA, Appel G, Hariri A, Liu S, Maski M, Shen Y, Zhang Q, Iqbal S, Kowthalam MU, Lin J, Ding J; HERA Clinical Trial Group (2024) A randomized controlled clinical trial testing effects of lademirsen on kidney function decline in adults with Alport syndrome. Clin J Am Soc Nephrol 19:9951004. https:\/\/doi.org\/10.2215\/CJN.0000000000000458","journal-title":"Clin J Am Soc Nephrol"},{"key":"7442_CR88","doi-asserted-by":"publisher","first-page":"101333","DOI":"10.1016\/j.omtm.2024.101333","volume":"32","author":"N Tavakolidakhrabadi","year":"2024","unstructured":"Tavakolidakhrabadi N, Ding WY, Saleem MA, Welsh GI, May C (2024) Gene therapy and kidney diseases. Mol Ther Methods Clin Dev 32:101333. https:\/\/doi.org\/10.1016\/j.omtm.2024.101333","journal-title":"Mol Ther Methods Clin Dev"},{"key":"7442_CR89","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.kint.2024.07.034","volume":"106","author":"V Khare","year":"2024","unstructured":"Khare V, Cherqui S (2024) Targeted gene therapy for rare genetic kidney diseases. Kidney Int 106:1051\u20131061. https:\/\/doi.org\/10.1016\/j.kint.2024.07.034","journal-title":"Kidney Int"},{"key":"7442_CR90","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.ymthe.2025.02.040","volume":"33","author":"D Wang","year":"2025","unstructured":"Wang D, Stevens G, Flotte TR (2025) Gene therapy then and now: a look back at changes in the field over the past 25 years. Mol Ther 33:1889\u20131902. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.040","journal-title":"Mol Ther"},{"key":"7442_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf332","volume":"19","author":"N Tavakolidakhrabadi","year":"2025","unstructured":"Tavakolidakhrabadi N, Ding WY, Welsh GI, Saleem MA (2025) Molecular mechanisms in podocytopathies: finding suitable targets for a new era of glomerular gene therapy. Clin Kidney J 19:sfaf332. https:\/\/doi.org\/10.1093\/ckj\/sfaf332","journal-title":"Clin Kidney J"},{"key":"7442_CR92","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41431-022-01075-0","volume":"30","author":"DG Ljubanovi\u0107","year":"2022","unstructured":"Ljubanovi\u0107 DG, Lennon R, Weinstock AB, Knebelmann B, Cerkauskaite A, Gear S, Gross O, Turner AN, Baldassarri M, Pinto AM, Renieri A (2022) The 2019 and 2021 international workshops on Alport syndrome. Eur J Hum Genet 30:507\u2013516. https:\/\/doi.org\/10.1038\/s41431-022-01075-0","journal-title":"Eur J Hum Genet"},{"key":"7442_CR93","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1681\/ASN.0000000897","volume":"37","author":"MN Rheault","year":"2026","unstructured":"Rheault MN (2026) Treatment approaches for Alport syndrome. J Am Soc Nephrol 37:172\u2013179. https:\/\/doi.org\/10.1681\/ASN.0000000897","journal-title":"J Am Soc Nephrol"},{"key":"7442_CR94","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00467-025-07046-z","volume":"41","author":"C Lo Re","year":"2026","unstructured":"Lo Re C, Kim JJ, Fornoni A (2026) From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome. Pediatr Nephrol 41:607\u2013619. https:\/\/doi.org\/10.1007\/s00467-025-07046-z","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07442-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07442-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07442-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:54:02Z","timestamp":1792104842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07442-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":94,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7442"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07442-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}